Try our beta test site
7 studies found for:    Lymphoma OR CLL | palbociclib
Show Display Options
Rank Status Study
1 Recruiting Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma
Condition: Recurrent Mantle Cell Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Palbociclib;   Other: Pharmacological Study
2 Active, not recruiting Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: PD 0332991;   Drug: bortezomib
3 Completed
Has Results
An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.
Condition: Lymphoma, Mantle-Cell
Intervention: Drug: PD-0332991
4 Completed
Has Results
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Conditions: Neoplasms;   Lymphoma, Non-Hodgkin
Intervention: Drug: PD-0332991
5 Recruiting TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Conditions: Lymphoma, Non-Hodgkin;   Multiple Myeloma;   Advanced Solid Tumors
Interventions: Drug: Erlotinib;   Drug: Axitinib;   Drug: Bosutinib;   Drug: Crizotinib;   Drug: Palbociclib;   Drug: Sunitinib;   Drug: Temsirolimus;   Drug: Trastuzumab and Pertuzumab;   Drug: Vemurafenib and Cobimetinib;   Drug: Vismodegib;   Drug: Cetuximab;   Drug: Dasatinib;   Drug: Regorafenib;   Drug: Olaparib;   Drug: Pembrolizumab
6 Recruiting NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma
Conditions: Advanced Malignant Neoplasm;   Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Plasma Cell Myeloma;   Refractory Malignant Neoplasm;   Refractory Plasma Cell Myeloma
Interventions: Drug: Afatinib;   Drug: Akt inhibitor AZD5363;   Drug: Binimetinib;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dasatinib;   Drug: Defactinib;   Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab Emtansine;   Drug: Trk Inhibitor LOXO-101;   Drug: Vismodegib;   Drug: WEE1 Inhibitor AZD1775
7 Recruiting Study of Palbociclib in MLL-rearranged Acute Leukemias
Conditions: Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia
Intervention: Drug: Palbociclib

Study has passed its completion date and status has not been verified in more than two years.